TARSA THERAPEUTICS
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
TARSA THERAPEUTICS
Industry:
Biotechnology Medical Medical Device
Founded:
2009-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.tarsatherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
267-273-7940
Total Funding:
124.25 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon WordPress Google Analytics SSL By Default HSTS Organization Schema Sitelinks Search Box
Similar Organizations
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
CONMED
CONMED Corporation is a global medical technology company that specializes in the development.
Evernow
Evernow is a provider of women's health care services before, during, and after menopause.
Genecis
Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into high value materials.
HAYA Therapeutics
HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.
Impulse Dynamics
Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF).
Neuro42
Neuro42 is developing and commercializing advanced MRI technology for diagnosis and image-guided interventions.
Vertos Medical
Vertos Medical is a healthcare company that develops and markets medical devices that are used for the treatment of common spinal diseases.
Current Advisors List
Board_member
Board_member
Board_member
2009-01-01
Board_member
Current Employees Featured
George R. Maurer Vice President CMC and Supply @ Tarsa Therapeutics
Vice President CMC and Supply
David Krause Chief Medical Officer @ Tarsa Therapeutics
Chief Medical Officer
David Brand President, Founder & Chief Executive Officer, Director @ Tarsa Therapeutics
President, Founder & Chief Executive Officer, Director
2009-03-01
Thomas Wicks Vice President of Global RA / QA @ Tarsa Therapeutics
Vice President of Global RA / QA
2009-11-01
Founder
Investors List
Square 1 Bank
Square 1 Bank investment in Debt Financing - Tarsa Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Tarsa Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Tarsa Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Tarsa Therapeutics
Quaker Partners
Quaker Partners investment in Series B - Tarsa Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Series B - Tarsa Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Tarsa Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Series B - Tarsa Therapeutics
Marker
Marker investment in Series B - Tarsa Therapeutics
Quaker BioVentures
Quaker BioVentures investment in Series B - Tarsa Therapeutics
Official Site Inspections
http://www.tarsatherapeutics.com
- Host name: redirect-v225.secureserver.net
- IP address: 184.168.47.225
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
Tarsatherapeutics.com lookup results from whois.register.com server:
- Domain created: 7th-Apr-2009
- Domain updated: 2nd-Apr-2025
- Domain expires: 7th-Apr-2028 2 Years, 354 Days left
- Website age: 16 Years, 11 Days
- Registrar Domain ID: 1551570282_DOMAIN_COM-VRSN
- Registrar Url: http://www.register.com
- Registrar WHOIS Server: whois.register.com
- Registrar Abuse Contact Email: domain.operations@web.com
- Registrar Abuse Contact Phone: +1.8777228662
- Name server:
- DNS101.REGISTER.COM
- DNS102.REGISTER.COM
More informations about "Tarsa Therapeutics"
Theratechnologies Receives FDA Approval for EGRIFTA WR™ …
New, improved formulation set to replace EGRIFTA SV ®. MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) …See details»
New study results reinforce Tagrisso as the backbone therapy for …
Mar 25, 2025 New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as …See details»
Home - Tarsa Therapeutics
R-Pharm JSC acquires rights to Tarsa’s TBRIA™, novel oral treatment for post-menopausal osteoporosis Tarsa Therapeutics developed TBRIA™, a novel oral formulation of calcitonin for …See details»
Tarsa Therapeutics - 2025 Company Profile - Tracxn
Mar 21, 2025 Tarsa Therapeutics - Developer of oral treatment for postmenopausal osteoporosis. Raised a total funding of $76.7M over 9 rounds from 7 investors. Founded by …See details»
Tarsa Therapeutics - Crunchbase Company Profile & Funding
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.See details»
Nextsource | Company Profile | Tarsa Therapeutics
Explore the company profile of Tarsa Therapeutics (tarsatherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Tarsa Therapeutics | VentureRadar
Website: http://www.tarsatherapeutics.com. Tarsa Therapeutics is developing OSTORA?, a novel oral formulation of calcitonin for the treatment and prevention of ...See details»
Tarsa Therapeutics, Inc - Company Profile & Staff Directory
Tarsa Therapeutics, Inc is a Pharmaceuticals company located in 1628 John F. Kennedy Boulevard 8 Penn Center Suite 1400, Philadelphia, Pennsylvania 19103, US with 2 …See details»
Tarsa Therapeutics - Craft
Tarsa Therapeutics $95.6 m in total funding,. See insights on Tarsa Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Tarsa Therapeutics, Inc overview - services, products, equipment …
Learn about Tarsa Therapeutics, Inc - locations, products, equipment, revenue, and target industries. Read the latest news, find similar companies and employees, and moreSee details»
Tarsa Therapeutics - Products, Competitors, Financials, Employees ...
Headquarters Location. 8 Penn Center 1628 JFK Blvd Suite 1400. Philadelphia, Pennsylvania, 19103, United States. 267-273-7940See details»
Tarsa Therapeutics - Overview, News & Similar companies
View Tarsa Therapeutics (www.tarsatherapeutics.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
New study results reinforce TAGRISSO® (osimertinib) as the …
Mar 25, 2025 New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO ® (osimertinib), as …See details»
Tarsa Therapeutics, Inc. Company Profile | Philadelphia, PA ...
Find company research, competitor information, contact details & financial data for Tarsa Therapeutics, Inc. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
Tarsa Therapeutics Company Profile | Management and ... - Datanyze
Tarsa Therapeutics Profile and History . Tarsa Therapeutics is a venture-backed clinical stage biotechnology company developing OSTORA™, an oral formulation of calcitonin for the …See details»
Tarsa Therapeutics 2025 Company Profile: Valuation, Investors ...
Information on acquisition, funding, investors, and executives for Tarsa Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
tarsatherapeutics.com - Home - Tarsa Therapeutics - Sur.ly
Popular pages. Home - Tarsa Therapeutics. R-Pharm JSC acquires rights to Tarsa’s TBRIA™, novel oral treatment for post-menopausal osteoporosis Tarsa Therapeutics developed …See details»
Tarsa Therapeutics, Inc. (Tarsa Therapeutics, Inc.) - 药物管线_专利_ …
了解Tarsa Therapeutics, Inc. (Tarsa Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验和1篇文献，药物:Recombinant Salmon Calcitonin(Tarsa …See details»
TARSA THERAPEUTICS Revenue, Growth & Competitor Profile
Trademark Applications Trademark applications show the products and services that Tarsa Therapeutics is developing and marketing. Tarsa Therapeutics doesn't have any recent …See details»
Tarsa Therapeutics Completes $28 Million Series B Financing to …
PHILADELPHIA, PA – March 16, 2012 — Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital. James …See details»